8.3 Neonatal Abstinence Syndrome (NAS) & Toxicology

8.3 Neonatal Abstinence Syndrome (NAS) & Toxicology

Neonatal Abstinence Syndrome (NAS), increasingly referred to as Neonatal Opioid Withdrawal Syndrome (NOWS) when specifically caused by opioids, is a complex of physical and behavioral withdrawal symptoms that occurs in newborns exposed to addictive substances in utero. While opioids (such as heroin, methadone, buprenorphine, and prescription pain medications) are the primary culprits, NAS can also be precipitated by prenatal exposure to benzodiazepines, barbiturates, selective serotonin reuptake inhibitors (SSRIs), and nicotine. Managing these infants requires a standardized, multi-disciplinary approach focused on symptom stabilization, maternal-infant bonding, and appropriate pharmacotherapy.

---

Pathophysiology of Withdrawal

Prenatal exposure leads to the active transport of lipophilic substances across the placenta, resulting in chronic fetal exposure and physiological dependence.

• Opioid Mechanism: Opioids bind to mu-opioid receptors in the central nervous system (CNS) and gastrointestinal (GI) tract. This binding inhibits the enzyme adenylate cyclase, reducing intracellular cyclic adenosine monophosphate (cAMP) and decreasing the release of neurotransmitters (specifically norepinephrine).
• Abrupt Cessation: At birth, the separation from the placenta leads to an abrupt cessation of the drug supply.
• Rebound Effect: The lack of receptor stimulation triggers a rebound increase in adenylate cyclase activity, causing an efflux of cAMP and a massive surge of norepinephrine. This noradrenergic storm is responsible for the autonomic hyperactivity and central nervous system hyperirritability that define NAS.

---

Clinical Manifestations

The onset of withdrawal symptoms varies based on the half-life of the drug:

• Short-acting opioids (heroin, fentanyl): Symptoms typically appear within 24 to 48 hours of life.
• Long-acting opioids (methadone, buprenorphine): Symptoms typically appear within 72 to 96 hours of life but can be delayed for up to 2 weeks.
• Non-opioids (SSRIs, benzodiazepines): Symptoms typically appear within 24 to 72 hours of life.

The clinical signs of NAS are grouped into three primary categories:

Symptom Classification

---

Scoring Systems and Assessment

Standardized tools are used to objectively monitor withdrawal severity and guide treatment decisions.

Finnegan Neonatal Abstinence Scoring System (FNASS)

The FNASS is a 21-item scoring sheet that evaluates the severity of withdrawal symptoms.

• Frequency: Scored every 3 to 4 hours, typically 1 to 2 hours after a feeding when the infant is in a quiet state.
• Method: The score reflects the worst symptoms observed during the entire scoring interval.
• Treatment Threshold: Pharmacological therapy is initiated if the infant has three consecutive Finnegan scores \ge8 or two consecutive scores \ge12.

Eat, Sleep, Console (ESC) Methodology

ESC is a newer, function-based assessment model that focuses on the infant's functional ability rather than individual withdrawal signs. It asks three key questions:

1. Eat: Can the infant eat effectively? (breastfeed successfully or consume \ge1 ounce of formula per feed)?
2. Sleep: Can the infant sleep undisturbed for \ge1 hour after feeding?
3. Console: Can the infant be consoled within 10 minutes by a caregiver utilizing non-pharmacological soothing techniques? If the infant fails any of these criteria due to withdrawal, non-pharmacological interventions are maximized (e.g., rooming-in, parental presence). Pharmacological therapy is initiated only if the infant cannot perform these functions despite optimized non-pharmacological care. ESC has significantly reduced the rate of pharmacological treatment and hospital length of stay compared to the FNASS.

---

Non-Pharmacological Management

Non-pharmacological interventions are the first line of therapy and must be implemented for all drug-exposed newborns. These include:

• Environmental Modification: Maintain a quiet, low-stimulus environment with dim lights and minimal noise. Cluster care to avoid overstimulation.
• Positioning and Comfort: Snug swaddling in a flexed position helps control tremors and prevents startle reflexes. Practice frequent skin-to-skin contact (kangaroo care).
• Soothing Techniques: Rhythmic vertical rocking, pacifier use for non-nutritive sucking, and application of barrier creams to prevent skin excoriations from rubbing.
• Nutrition: Provide demand feedings. High-calorie formulas (22 or 24 kcal/oz) may be necessary to support the infant's hypermetabolic state and prevent weight loss.
• Breastfeeding: Strongly encouraged if the mother is participating in a stable, supervised substance treatment program, has negative urine drug screens for illicit substances, and has no other contraindications (such as HIV infection). Trace amounts of methadone or buprenorphine in breast milk help ease the infant's withdrawal.

---

Pharmacological Management

Pharmacological therapy is indicated when non-pharmacological measures fail, when FNASS scores exceed thresholds, or when there is severe functional impairment (e.g., weight loss >10%, intractable vomiting, or seizures).

First-Line Agents (Opioids)

• Oral Morphine Sulfate: The most widely used medication. It has a short half-life, allowing for rapid titration based on weight and symptom scores. Once stabilized, the dose is weaned gradually (typically by 10% of the maximum dose every 24–48 hours).
• Methadone: A synthetic opioid with a longer half-life, providing more stable serum concentrations and requiring less frequent dosing. However, it takes longer to reach steady state and can accumulate, leading to prolonged weaning.

Second-Line and Adjunctive Agents

• Phenobarbital: The drug of choice for infants with polydrug exposure (e.g., opioids plus benzodiazepines, alcohol, or barbiturates) or for pure non-opioid withdrawal. It acts as a CNS sedative but does not target opioid receptors. If used as an adjunct to morphine, it helps reduce CNS symptoms but can cause significant sedation.
• Clonidine: An alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system, thereby mitigating autonomic symptoms. It can be used as an adjunct to reduce the morphine requirement or as a primary agent. The nurse must monitor for hypotension and bradycardia.

---

Toxicology Screening

To confirm intrauterine drug exposure, the following specimens can be analyzed:

• Urine: Reflects immediate, recent maternal drug use (past 24–72 hours prior to birth). It has a high rate of false negatives if the sample is not collected immediately after birth or if the drug has a short half-life.
• Meconium: The historical standard for long-term exposure. Meconium begins to accumulate in the fetal intestine around the 20th week of gestation, providing a cumulative record of exposure. However, collection can be delayed, and laboratory processing takes several days.
• Umbilical Cord Tissue: The current preferred specimen in many NICUs. A 6-inch segment of the umbilical cord is collected at birth. It provides a similar detection window to meconium (second and third trimesters), is easily collected immediately, and offers a rapid laboratory turnaround time (often within 24 hours).

---

Exam Traps

• Naloxone Contraindication: Never administer Naloxone (Narcan) to an infant born to an opioid-dependent mother. Naloxone will block the opioid receptors abruptly, precipitating acute, severe, life-threatening withdrawal, which can cause severe seizures and cardiovascular collapse.
• Breastfeeding Rules: Do not discourage breastfeeding solely because the mother is taking prescribed methadone or buprenorphine. As long as she is compliant with a treatment program, breastfeeding is highly beneficial and therapeutic for the infant.